For the quarter ended March 2025, Bausch + Lomb (BLCO) reported revenue of $1.14 billion, up 3.5% over the same period last year. EPS came in at -$0.07, compared to $0.07 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.15 billion, representing a surprise of -0.86%. The company delivered an EPS surprise of -333.33%, with the consensus EPS estimate being $0.03.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Vision Care: $656 million compared to the $654.55 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year.
- Revenues- Surgical: $214 million versus the three-analyst average estimate of $206.66 million. The reported number represents a year-over-year change of +8.6%.
- Revenues- Pharmaceuticals: $267 million versus the three-analyst average estimate of $284.94 million. The reported number represents a year-over-year change of 0%.
- Revenues- Product sales: $1.13 billion compared to the $1.15 billion average estimate based on three analysts. The reported number represents a change of +3.6% year over year.
- Revenues- Other revenues: $4 million compared to the $5 million average estimate based on two analysts. The reported number represents a change of -20% year over year.
View all Key Company Metrics for Bausch + Lomb here>>>
Shares of Bausch + Lomb have returned -2.7% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch + Lomb Corporation (BLCO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
